What is Amber TX?
Amber Therapeutics is a medical technology innovator focused on the development of adaptive neuromodulation therapies. The company's flagship asset, the Picostim System, is a sophisticated, fully implantable device engineered to interface with the pudendal nerve. By dynamically adjusting to individual physiological responses, the system offers a personalized approach to treating mixed urinary incontinence. This condition affects approximately 40 million women in the United States, yet remains significantly underserved by existing therapeutic modalities. Since its inception in 2021, Amber TX has leveraged a multi-disciplinary team to bridge the gap between complex neuro-engineering and clinical application, aiming to establish a new paradigm in pelvic health management.
How much funding has Amber TX raised?
Amber TX has raised a total of $100M across 1 funding round:
Series A
$100M
Series A (2024): $100M with participation from F-Prime Capital Partners, New Enterprise Associates, and Lightstone Ventures
Key Investors in Amber TX
F-Prime Capital Partners
A global venture capital firm with a deep focus on healthcare and technology, leveraging a team of scientists and clinicians to support transformative medical innovations.
New Enterprise Associates
A long-standing venture capital firm that partners with entrepreneurs to build large-scale, impactful businesses across the technology and healthcare sectors.
Lightstone Ventures
A specialized investment firm dedicated to backing founders who translate cutting-edge scientific research into viable medical therapies and technologies.
What's next for Amber TX?
The recent capital allocation is earmarked for scaling the development and clinical validation of the Picostim System. As the company transitions from early-stage research to a more mature operational phase, the focus will likely shift toward navigating regulatory pathways and expanding its clinical footprint. By addressing a high-prevalence, high-impact condition, Amber TX is strategically positioned to capture significant market share within the burgeoning neuro-tech sector. Future milestones will likely involve multi-center clinical trials and the refinement of its adaptive algorithms to ensure long-term efficacy and patient safety, ultimately aiming to provide a definitive solution for millions of patients currently lacking effective treatment options.
See full Amber TX company page
